It has been shown that diabetes and hypertension treatments with angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin II type I receptor blockers (ARBs) increase angiotensin-converting enzyme 2 (ACE2) expression which consequently raises the risk of developing severe and fatal complications. This evidence concerns the gene ACE2 and diabetes mellitus.